Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor1


      Rosuvastatin (formerly known as ZD4522) is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) with distinct pharmacologic properties. Compared with most other statins, it is relatively hydrophilic, similar in this respect to pravastatin. Rosuvastatin has been shown to be a comparatively potent inhibitor of HMG-CoA reductase activity in a purified preparation of the catalytic domain of the human enzyme, as well as in rat and human hepatic microsomes. In rat hepatocytes, rosuvastatin was found to have significantly higher potency as an inhibitor of cholesterol synthesis than 5 other statins. Rosuvastatin was approximately 1,000-fold more potent in rat hepatocytes than in rat fibroblasts. Further studies in rat hepatocytes demonstrated that rosuvastatin is taken up into these cells by a high-affinity active uptake process. Rosuvastatin was also taken up selectively into the liver after intravenous administration in rats. Potent and prolonged HMG-CoA reductase inhibitory activity has been demonstrated after oral administration to rats and dogs. Pharmacokinetic studies in humans using oral doses of 5 to 80 mg showed that maximum plasma concentrations and areas under the concentration-time curve are approximately linear with dose. The terminal half-life is approximately 20 hours. Studies with human hepatic microsomes and human hepatocytes have suggested little or no metabolism via the cytochrome P-450 3A4 isoenzyme. On the basis of these observations, it is suggested that rosuvastatin has the potential to exert a profound effect on atherogenic lipoproteins.
      To read this article in full you will need to make a payment


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gotto Jr, A.M
        • Grundy S.M
        Lowering LDL cholesterol.
        Circulation. 1999; 99: E1-E7
        • Buckett L
        • Ballard P
        • Davidson R
        • Dunkley C
        • Martin L
        • Stafford J
        • McTaggart F
        Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells.
        Atherosclerosis. 2000; 151 (Abstr.): 41
        • Smith G
        • Davidson R
        • Bloor S
        • Burns K
        • Calnan C
        • McAulay P
        • Torr N
        • Ward W
        • McTaggart F
        Pharmacological properties of ZD4522.
        Atherosclerosis. 2000; 151 (Abstr.): 39
      1. Data on file, AstraZeneca, 2000.

        • Nezasa K
        • Higaki K
        • Hasegawa H
        • Inazawa K
        • Takeuchi M
        • Yukawa T
        • McTaggart F
        • Nakano M
        Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat.
        Atherosclerosis. 2000; 151 (Abstr.): 39
        • Warwick M.J
        • Dane A.L
        • Raza A
        • Schneck D.W
        Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522.
        Atherosclerosis. 2000; 151 (Abstr.): 39
        • Knopp R.H
        Drug treatment of lipid disorders.
        N Engl J Med. 1999; 341: 498-511
        • McCormick A.D
        • McKillop D
        • Bulters C.J
        • Miles G.S
        • Baba T
        • Touchi A
        • Yamaguchi Y
        J Clin Pharmacol. 2000; 40 (Abstr.): 1055